טוען...
Targeted therapy for fusion-driven high-risk acute leukemia
Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend hig...
שמור ב:
| הוצא לאור ב: | Blood |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6148448/ https://ncbi.nlm.nih.gov/pubmed/30049809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-04-784157 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|